243 related articles for article (PubMed ID: 35662158)
1. [An overview of histiocytosis].
Tojo A
Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
Allen CE; Parsons DW
Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
[TBL] [Abstract][Full Text] [Related]
4. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
5. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
[TBL] [Abstract][Full Text] [Related]
7. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
8. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
9. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adult xanthogranuloma with a small portion of BRAF
Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
[TBL] [Abstract][Full Text] [Related]
11. Impact of
Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
[TBL] [Abstract][Full Text] [Related]
12. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
13. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
[TBL] [Abstract][Full Text] [Related]
14. Histiocytic disorders.
McClain KL; Bigenwald C; Collin M; Haroche J; Marsh RA; Merad M; Picarsic J; Ribeiro KB; Allen CE
Nat Rev Dis Primers; 2021 Oct; 7(1):73. PubMed ID: 34620874
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
16. Langerhans cell histiocytosis: Version 2021.
Gulati N; Allen CE
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):15-23. PubMed ID: 34105821
[TBL] [Abstract][Full Text] [Related]
17. Histiocytosis.
Rocamora-Blanch G; Climent F; Solanich X
Med Clin (Barc); 2023 Aug; 161(4):166-175. PubMed ID: 37263840
[TBL] [Abstract][Full Text] [Related]
18. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
[TBL] [Abstract][Full Text] [Related]
19. Molecular and clinicopathologic characterization of pediatric histiocytoses.
Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]